COVID-19 Vaccines and the Development of New LUTS
Completed
- Conditions
- COVID-19 Vaccine Adverse ReactionLower Urinary Tract Symptoms
- Registration Number
- NCT05582525
- Lead Sponsor
- The Hashemite University
- Brief Summary
This study was conducted to check whether coronavirus disease 2019 (COVID) vaccines have a relationship with LUTS or not in a healthy and mostly medically free population.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 341
Inclusion Criteria
- Medical Student
- Having had a COVID-19 Vaccine
Exclusion Criteria
None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method New Lower Urinary Tract Symptoms 2-3 months Only after having had any COVID -19 vaccine
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link SARS-CoV-2 vaccines to lower urinary tract symptoms in healthy populations?
How do LUTS incidence rates post-COVID-19 vaccination compare to standard-of-care urological treatments in medical students?
Are specific biomarkers associated with vaccine-induced LUTS development in young adults with no prior urological conditions?
What adverse event management strategies are effective for vaccine-related lower urinary tract symptoms in clinical practice?
How do mRNA and non-mRNA COVID-19 vaccines compare in their association with new-onset LUTS in medically free cohorts?
Trial Locations
- Locations (1)
The Hashemite University
🇯🇴Zarqa, Jordan
The Hashemite University🇯🇴Zarqa, Jordan